MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Etoricoxib

CAS No. : 202409-33-4

MCE 国际站：Etoricoxib

产品活性：Etoricoxib (MK-0663) 是一种非甾体抗炎剂，为可口服的、选择性的 COX-2 抑制剂，对人全血 COX-2 和 COX-1 的 IC₅₀ 值分别为 1.1 µM 和 116 µM。

研究领域：Immunology/Inflammation

作用靶点：COX

In Vitro: Etoricoxib (MK-0663) is a selective and orally active COX-2 inhibitor, with IC₅₀s of 1.1 µM, 116 µM and 5 µM for COX-2, COX-1 in human whole blood and purified human COX-2, respectively. Etoricoxib (MK-0663) shows inhibitory effect on PGE2 production by CHO (COX-2) cells (IC₅₀, 79 nM), on purified human COX-2 with detergent (IC₅₀, 4.1 µM), and on purified PGE2 production by U937 microsomes (low substrate; IC₅₀, 12.1 µM). However, Etoricoxib (MK-0663) has little activity against COX-1 with a K_i of 167 µM.

In Vivo: Etoricoxib (MK-0663) (0.1-30 mg/kg, p.o.) dose-dependently inhibits carrageenan-induced paw edema, carrageenan-induced paw hyperalgesia, and endotoxin-induced pyresis in rats. Etoricoxib (≥10 mg/kg) completely reverses hyperalgesia response in the rat hyperalgesia model. Etoricoxib (MK-0663) (200 mg/kg/day) has no effect on urinary ⁵¹Cr excretion in rats, and nor in monkeys at 100 mg/kg/day. Etoricoxib (MK-0663) (50 and 100 mg/kg) potently increases the malondialdehyde (MDA) and myeloperoxidase (MPO) levels, and decreases the total glutathione (tGSH) and glutathione reductase (GSHRd) levels in rats. Etoricoxib (MK-0663) (100 mg/kg) significantly inhibits the decrease of NO in rats. Etoricoxib (MK-0663) (0.64 mg/kg, p.o.) reduces the features such as multiple plaque lesions, hyperplasia and dysplasia induced by 1,2-dimethylhydrazine dihydrochloride (DMH) in rats.

相关产品：Drug Repurposing Compound Library Plus | FDA-Approved Drug Library Plus | FDA-Approved Drug Library Mini | Bioactive Compound Library Plus | Immunology/Inflammation Compound Library | FDA-Approved Drug Library | Anti-Cancer Compound Library | Anti-Aging Compound Library | Drug Repurposing Compound Library | Anti-COVID-19 Compound Library | Pyroptosis Compound Library | Orally Active Compound Library | FDA Approved & Pharmacopeial Drug Library | Anti-Pancreatic Cancer Compound Library | Acetaminophen | Indomethacin | Celecoxib | Aspirin | Ibuprofen | Catechin | NS-398 | Diclofenac | 20(S)-Ginsenoside Rg3 | Naproxen | (-)-Epicatechin | Gallic acid | Xanthohumol | Sulindac | SC-560 | Carprofen | Salicylic acid | Meloxicam | Rutaecarpine | Rebamipide | Iguratimod | Flufenamic acid | Fenofibric acid | Isoorientin | Nabumetone | Neochlorogenic acid | Piroxicam | Rofecoxib

品牌介绍:
• MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供最新最全的高品质小分子活性化合物；
• 10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
• 设有专业的实验中心和严格的质控、验证体系；
• 提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
• 产品的生物活性多经各国客户实验验证；
• Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果；
• 专业团队跟踪最新的制药及生命科学研究进展，为您提供全球最新的活性化合物；
• 与世界各大制药公司及知名科研机构建立了长期的合作。